Pseudohypoparathyroidism secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 7: Line 7:
Secondary prevention measures in pseudohypoparathyroidism include:<ref name="pmid22736772">{{cite journal |vauthors=Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS |title=Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B |journal=J. Clin. Endocrinol. Metab. |volume=97 |issue=9 |pages=3025–30 |year=2012 |pmid=22736772 |pmc=3431579 |doi=10.1210/jc.2012-1655 |url=}}</ref>
Secondary prevention measures in pseudohypoparathyroidism include:<ref name="pmid22736772">{{cite journal |vauthors=Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS |title=Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B |journal=J. Clin. Endocrinol. Metab. |volume=97 |issue=9 |pages=3025–30 |year=2012 |pmid=22736772 |pmc=3431579 |doi=10.1210/jc.2012-1655 |url=}}</ref>
* Monitor therapy with regular serum and urinary [[calcium]] measurements
* Monitor therapy with regular serum and urinary [[calcium]] measurements
* Pseudohypoparathyroidism type 1b patients at an increased risk of developing [[hyperparathyroidism]] and [[hyperparathyroid]] bone disease should be maintained at sufficient doses of [[calcium]] and [[vitamin D]] to maintain serum [[calcium]] and [[PTH]] levels within the normal range
* Pseudohypoparathyroidism type 1b patients at an increased risk of developing [[hyperparathyroidism]] and [[hyperparathyroid]] bone disease should be maintained at sufficient doses of [[calcium]] and [[vitamin D]] to maintain serum [[calcium]] and [[PTH]] levels within the normal range.


==References==
==References==

Latest revision as of 21:13, 17 October 2017

Pseudohypoparathyroidism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pseudohypoparathyroidism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pseudohypoparathyroidism secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pseudohypoparathyroidism secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pseudohypoparathyroidism secondary prevention

CDC on Pseudohypoparathyroidism secondary prevention

Pseudohypoparathyroidism secondary prevention in the news

Blogs on Pseudohypoparathyroidism secondary prevention

Directions to Hospitals Treating Pseudohypoparathyroidism

Risk calculators and risk factors for Pseudohypoparathyroidism secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Overview

Secondary prevention of measures in pseudohypoparathyroidism include regular serum and urinary calcium measurements monitoring.

Secondary Prevention

Secondary prevention measures in pseudohypoparathyroidism include:[1]

References

  1. Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS (2012). "Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B". J. Clin. Endocrinol. Metab. 97 (9): 3025–30. doi:10.1210/jc.2012-1655. PMC 3431579. PMID 22736772.


Template:WikiDoc Sources